Genomic Expression Inc

Genomic Expression Inc.?is partnering with?Mona Jhaveri?and?Music Beats Cancer?(not-for-profit) to raise funding for?#Ovarian?#cancer. Ovarian cancer is one of the toughest cancers to treat, and overcoming it can be a real challenge. Right now, treatment options are mostly a combination of surgery and #chemotherapy, with newer targeted therapies helping some patients. Unfortunately, most women with ovarian cancer face a recurrence within 18-24 months. When the cancer comes back—especially if it becomes platinum-resistant and stops responding to standard chemotherapy—treatment options become even more limited and less effective. There is hope! Genomic Expression Inc's OneRNA? Platform is an exciting new #clinical tool designed to #individualize cancer treatment. #quantifying?all 20,000 mRNA markers from a single patient sample #OneRNA identifies the most effective treatment options for each individual. Our #breakthrough technology has been clinically validated in #breast and ovarian cancer, achieving an impressive #diagnostic yield of nearly 100%— that means treatment options for all patients are identified. A huge improvement compared to the 26% yield from traditional methods. With innovations like this, the future of cancer treatment is becoming more effective and truly individualized. Please support us in bringing this life-saving innovation to #patients https://lnkd.in/emNB88Za

Interview with Gitte Pedersen, CEO on her journey from #scientist to #entrepreneur by Sharron Cox "She Leads Biotech" https://lnkd.in/eHx5a6_K

Biotech was Grandpa’s Bet; Tech Bio is for the AI Generation Biotech is a science-driven industry that emerged from academic labs in the 70s and 80s. It’s very different from Tech Bio. Tech Bio firms tend to be leaner, founder-led, and, most importantly, driven by technology. They can generate #revenue faster, and they’re focused on fundamental innovation that delivers superior products defined by new technical approaches. Genomic Expression is a #techbio company leveraging #RNA #AI by building a tech stack that is exponentially scalable and disease-agnostic Read about Techbio here https://lnkd.in/ewwtscq3

At Genomic Expression Inc, we are excited to present at Drug R&D on Monday, February 10, in Boston. Our #OneRNA? Platform enables the #digitalization of #biomarkers leveraging #AI to translate massive amounts of data into insight and better treatment options for patients. For biotech and pharma, that means saving $1M upfront on validating a single biomarker, which is, at best, an enrichment marker. OneRNA is de-risking and accelerating clinical development through better trial design, identification of the right companion drug for your?#immune-oncology asset, or leveraging?#sythetic?#lethality. There is a reason why we have not "cured" cancer. We are simply doing it wrong. Today, drug development costs $2B and takes 10 years with a 5% success rate! Defining the real responders can enable #FDA breakthrough designation and get approvals in 5 years for less than $200M. Algorithms/AI leveraging #RNA are discovered at a rapid scale of 19,000 alone in 2024 in oncology; however, only a few #algorithms make it through clinical validation and into the clinical. Our OneRNA platform can solve that problem. #RNA is the cell software that provides the necessary information to understand the growth mechanisms and how to interrogate them through #drug intervention. Finally,?#OneRNA?can increase the drug label of already approved drugs by identifying the right responder segment across tumor types. Looking forward to meeting everybody on Monday Heidi B Morten Lorentz Pedersen

Final 24 hours: This is your chance to #invest in a company rewriting cancer treatment through #RNA #AI. Last Chance to Invest In this Round Our StartEngine campaign ends in 24hr -> February 6th, 2025, at 11:59 PST. Invest as little as $250 -> https://lnkd.in/enQ4F4GA Genomic Expression's breakthrough technology transforms how we treat cancer and develop drugs. The OneRNA? platform is commercially ready to launch in breast and ovarian cancer. Proof of concept in all major as well as some smaller cancer types. We're positioned for impact with significant strategic partnerships in the pipeline, growing revenue, and a potential $3.5 M NCI contract. Our real-world impact is profound, with patients experiencing remarkable outcomes. From metastatic thyroid cancer patients achieving long-term remission to follicular lymphoma patients responding to novel drug combinations identified by OneRNA?, the platform has changed lives. Backed by $6.5M in grants, $1.7M in seed funding, and industry leaders like Harvard Business Angels. Our team and investors collectively created over $80B in enterprise value in biotech. We hosted an investor webcast yesterday, and if you missed it and are interested, just DM me here, and I can share.

Join us #TODAY at 11 AM EST for an exclusive #investor webinar with Genomic Expression Inc.'s visionary CEO, Gitte Pedersen, and CSO scientist and inventor Morten Lorentz Pedersen. Together with their dream team, they have been a pioneering force in #RNA #AI Gitte will share why RNA AI enables more efficient #healthcare delivery and how OneRNA? is already saving lives by matching cancer patients with effective treatments. Morten will answer any technical questions. Don't miss this final opportunity to get your #investment questions answered and learn how you could help transform cancer care through precision medicine. Please register for Zoom "Meet the Founders" event Febr 4th at 11 am EST https://lnkd.in/ern9VCaN When you register, you will receive an email confirmation, and in that is an email - feel free to send us questions before the event. Looking forward to meeting you #TODAY on Zoom This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.

There is nothing more powerful than #patients #testimonies. Our Northstar is saving #cancer patients' lives also when they have zero treatment options left. Here are some of their stories: 1) Metastatic thyroid cancer patient with no treatment options achieving long-term remission after OneRNA? identified a very abnormal gene expressed for which there was a drug in development. She enrolled in a clinical study; the drug was later approved. She has been in complete remission for +3 years (see the video attached). 2) A follicular lymphoma patient that had gone through 2 standard treatments but recurred very rapidly.?The patient later enrolled in a hashtag #clinical study with a promising new drug, which didn't work, and later in a cancer vaccine trial that also did not work. hashtag #OneRNA? was able to identify 2 drugs, both approved, that could work in combination, and this patient is now in complete remission for 2 years. We raised $6.5M in grants, but there are no grants for commercialization, which is why we are raising this round on StartEngine. OneRNA? is the only quantitative #RNA #AI-powered treatment navigation platform: OneRNA? has been tested in all major cancers and is now clinically validated in breast and ovarian cancer with close to 100% diagnostic yield, which means that?OneRNA matches the tumor RNA expression profile to an approved drug in ALL the 50-80% of patients that do not respond to standard treatment. Invest in us to bring this to more patients. The Payor code is established - $3,000/test, which means patients do not pay out of pocket. Pls join us on February 4th at 11 am EST for our Meet the Founders #Webinar Registration is mandatory - https://lnkd.in/ern9VCaN Link to StartEngine page https://lnkd.in/eHpPAEtR

Join us on February 4th at 11 AM EST for an exclusive #investor webinar with our visionary CEO, Gitte Pedersen and CSO scientist and inventor Morten Pedersen. Together, they have been a pioneering force in #RNA #AI technology. Gitte will share why RNA AI saves lives and enables more effective #healthcare OneRNA? is saving lives by matching cancer patients with effective treatments. Morten will answer any technical questions. Don't miss this final opportunity to get your #investment questions answered and learn how you could help transform cancer care through precision medicine. This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion. https://lnkd.in/esJqfkAh

Join us on February 4th at 11 AM EST for an exclusive webinar with Genomic Expression's visionary CEO, Gitte Pedersen, and scientific co-founder Morten Lorentz Pedersen. Register here -> https://lnkd.in/esJqfkAh Gitte Pedersen is a former Novo Nordisk executive and, together with Morten Pedersen, a pioneering force in #RNA #AI technology. Gitte will share why RNA AI enables healthcare and how #OneRNA? is already saving lives by matching #cancer patients with effective treatments. Don't miss this final opportunity to get your #investment questions answered and learn how you could help transform cancer care through precision medicine. This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.

Now, there are only 30 days left to invest in Genomic Expression! Genomic Expression's crowdfunding campaign will end on February 6 Genomic Expression is revolutionizing cancer treatment by analyzing tumor RNA and identifying the most effective therapies for patients leveraging proprietary algorithms and AI. Patient Success Stories:?The real-world impact is profound, with patients experiencing remarkable outcomes. From metastatic thyroid cancer patients achieving long-term remission to follicular lymphoma patients responding to novel drug combinations identified by OneRNA?, the platform has changed lives. Supported by a team that generated +$80B of value in Biotech:? Genomic Expression got to commercial launch of its RNA AI platform, called OneRNA? ?through $6.5M in grants, $1.7M in seed funding, and $4.5M in lifetime revenue and is supported by a team of investors that collectively generated more than $80B in enterprise value including Jesper Zeuthen, CMO and co-founder of GenMab ($14B market cap) and Dan Adams, founder of Biogen ($22B market cap) and Protein sciences (exit to Sanofi for $740M). In the future, the platform will be able to rapidly translate RNA code into novel and potentially individualized RNA Therapeutics. -> You can jump in with as little as $250.? https://lnkd.in/enQ4F4GA?